Gene therapy for advanced glaucoma
Part of Eyes & vision clinical trials.
This trial tests a gene therapy treatment called GVB-2001 for people with primary open angle glaucoma. It involves a one-time injection into the eye to help lower eye pressure, and could be an option if you have tried other treatments that haven't worked well enough.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have had primary open angle glaucoma for at least one year.
- You must be in generally good health with no major medical conditions.
- You are willing to follow all the study procedures and visits, including a safety check after one year.
- You still have high eye pressure (over 21 mmHg) even after using two or more eye drops.
- Depending on the group, you may need to have no vision in the treated eye, or you may need to have some vision and a clear drainage angle.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational drug called REGN22530 for people with mild to moderate primary open-angle glaucoma or ocular hypertension (high eye pressure). The goal is to see if it can safely lower eye pressure and protect vision.
This trial tests a new gene therapy called VG801 for people with Stargardt disease, a genetic condition that causes vision loss. The treatment aims to improve or slow vision loss by delivering a working copy of the ABCA4 gene to the retina.
This trial tests a gene therapy injection (UGX202) for people with advanced retinitis pigmentosa (RP) who have very poor vision. It aims to see if the treatment can help improve or preserve sight.
This study tests an eye drop (G01) for people with primary open-angle glaucoma that is getting worse despite current treatments. It aims to see if G01 can safely slow down or stop the progression of glaucoma.
This trial tests a gene therapy called GS010 given as an injection into the eye for people with vision loss from LHON. It aims to see if it can help improve vision in both eyes.
This trial tests a gene therapy injection into the eye to treat diabetic retinopathy (eye damage from diabetes) before it progresses. The goal is to slow or prevent vision loss and potentially delay the need for laser treatment or other injections.
Hear when a new Primary Open-Angle Glaucoma (POAG) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.